O ne of the most widely recognized functions of the reninangiotensin system (RAS) is its role in the regulation of arterial pressure. Angiotensin II (ANG II), the effector hormone of the RAS, regulates blood pressure by exerting both direct and indirect effects on a variety of cardiovascular tissues, including blood vessels, brain, and kidney. ANG II is generated by the serial cleavage of angiotensinogen (AGT) first by renin and then by angiotensin-converting enzyme (ACE). ANG II exerts its effects via two classes of receptors, AT 1 and AT 2 , with most of its classic actions mediated through the AT 1 receptor. Two subtypes of AT 1 receptor, AT 1A and AT 1B , that cannot be distinguished pharmacologically exist in rodents. Most of our current understanding of the RAS has come from pharmacological studies using inhibitors; however, the emergence of gene targeting has allowed us to dissect this system with a targeted specificity not previously possible.
Blood pressure regulation
The first gene-targeting studies on the RAS were performed on the renin substrate AGT (6) . AGT is synthesized in a wide variety of tissues, including the brain, kidney, and liver. Plasma levels are due to synthesis of the AGT in the liver, and gene variants that are associated with altered levels of AGT in the plasma have been correlated with human essential hypertension. In studies of mice with 1-4 copies of the AGT gene, blood pressure was increased by 8 mmHg per gene copy, with plasma AGT levels 35% (1 copy), 124% (3 copies), and 145% (4 copies) of wild type. This data supports the view that chronic alterations in plasma levels of AGT are able to affect blood pressure even in the presence of normal blood pressure regulatory mechanisms. Blood pressure data in AGT knockout mice has been difficult to obtain because of the lethality associated with altered renovascular development in these mice. However, the few measurements obtained indicated that blood pressure is dramatically decreased and dependent on sodium intake.
Gene knockouts have also been generated for ACE and renin (7, 15) . ACE knockout mice have blood pressure that is reduced by 15-20 mmHg from wild-type controls. As expected, ACE knockout mice fail to exhibit a pressor response to infusion of angiotensin I (ANG I) and exhibit an enhanced depressor response to infusions of bradykinin. The same renovascular pathologies that are present in AGT knockouts are also found in ACE knockout mice. The experimental situation is more complicated when considering renin because mice exhibit two genotypes at the renin locus. Some inbred strains, such as C57BL/6 and BALB/c, contain one renin gene (Ren-1   c   ) , and other strains, such as 129 and DBA, contain two renin genes (Ren-1 d and Ren-2). All three mouse renin genes are highly homologous but produce distinct proteins having different glycosylation potentials. Targeted disruption of all of the renin genes has been reported, with the major cardiovascular phenotype being a decrease in blood pressure in Ren-1 c homozygous knockout mice. These mice also lack detectable levels of plasma renin activity and ANG I; however, levels of ANG II were not measured in these mice (15) . Juxtaglomerular (JG) cells in Ren-1 d knockout mice lack secretory granules, suggesting differential sorting of renin-1 and renin-2 in the secretory pathway and perhaps a proactive role for renin in defining the "epithelioid" character of the JG cell. Most of the classic cardiovascular effects of ANG II have been attributed to the AT 1 receptor. In rodents, there are two unique AT 1 receptor subtypes, AT 1A and AT 1B , both of which are blocked by the general AT 1 receptor antagonist losartan. Since these receptor subtypes cannot be distinguished pharmacologically, gene-targeting studies have been critical in defining the role of each subtype in vivo. Mice with a targeted disruption of the AT 1A receptor exhibit a significant decrease in blood pressure that is further lowered by losartan treatment (9) . These mice also exhibit a markedly reduced, but not completely abolished, pressor response to ANG II infusion. These findings suggest a potential role for the AT 1B receptor in the regulation of blood pressure in the absence of the AT 1A receptor. Recently, we reported that the pressor response to centrally administered ANG II can be fully attributed to the AT 1A receptor, whereas the dipsogenic response to central ANG II administration is mediated by the AT 1B receptor (4). This is the first report describing a distinct and separate function for the AT 1B receptor.
The other major class of ANG II receptor is the AT 2 receptor. This receptor is believed to be involved in pathways that oppose the actions of the AT 1 receptor such as vasodilatation and apoptosis. Much of what is known about the function of the AT 2 receptor has come from gene deletion studies of the AT 2 receptor and from studies in mice lacking both the AT 1A and AT 1B receptors. Disruption of the AT 2 receptor was originally reported to have no effect on basal blood pressure; however, recent studies have detected an increase in blood pressure in mice lacking this gene (5, 12) . Although the effect of AT 2 receptor deletion is controversial, its role in the regulation of blood pressure may be important during blockade of the AT 1 receptor. Studies in mice lacking both AT 1 receptors have demonstrated that administration of captopril increases blood pressure, presumably because it prevents ANG II binding the AT 2 receptor (10). However, infusion of ANG II into these mice did not lower blood pressure as might be expected, and duplication of this effect with an AT 2 receptor antagonist has yet to be reported. Transgenic mice in which the AT 2 receptor is overexpressed specifically in vascular smooth muscle cells (VSMC) have been generated (14) . Chronic infusion of ANG II into these mice fails to elicit a pressor response unless accompanied by blockade of bradykinin type 2 receptor or nitric oxide synthase. This was associated with increased cGMP production in aortic explants and a markedly diminished ANG II-induced constriction, both of which were dependent on an intact endothelium.
Recently, a significant body of evidence has demonstrated that organs such as the kidney, heart, and brain contain a local tissue RAS that plays a significant role in the control of organ function and blood pressure regulation. To test whether alterations in the intrarenal RAS system are sufficient to affect blood pressure, we created a model in which the human AGT gene is specifically overexpressed in the proximal tubule of the kidney (a site where AGT is normally expressed in the kidney) (Fig. 1A) . Human AGT protein was elevated in urine but absent from plasma, suggesting apical secretion of the protein into the lumen. When crossed with mice carrying the human renin gene, the resultant double transgenic mice were hypertensive (2) (Fig. 1B) . Interestingly, the hypertension displayed by the double transgenic mice was not associated with any increase in the plasma levels of ANG II (Fig. 1C) . Moreover, acute intravenous infusion of losartan was unable to normalize pressure in these mice, further suggesting that the observed hypertension was due to increase in intrarenal (perhaps proximal tubular) levels of ANG II (Fig. 1D) . These results provide experimental proof that alterations in intrarenal RAS function may cause elevated arterial pressure without affecting the endocrine RAS.
Renal function
The RAS plays a key role in the regulation of renal function under basal conditions and in response to various hormonal and environmental factors. The RAS is also believed to play a key role in the regulation of glomerular filtration, in part through the tubuloglomerular feedback (TGF) mechanism and its direct constrictor actions on renal arterioles. Although technically challenging, TGF responses measured by stopflow pressures in response to increases in perfusion rate revealed a lack of a TGF response in ACE and AT 1A knockout mice (11) . Administration of exogenous ANG II was able to completely restore the TGF response in ACE but not in AT 1A knockout mice, suggesting that the TGF response in the mouse may be modulated via the AT 1A receptor either at the afferent arteriole or the macula densa.
Further examination of renal hemodynamics in AT 1A knockout mice failed to find any differences in GFR and RPF compared with wild-type mice under basal conditions or in response to volume expansion. This is in contrast to studies performed on AGT knockout mice in which autoregulation of GFR was found to be absent in response to changes in sodium intake (8) . These data suggest that in AT 1A knockout mice compensation by either AT 1B or AT 2 receptor may allow for the maintenance of normal renal hemodynamics in the face of lower blood pressure. However, in the AGT knockout mouse, these receptors are not able to compensate for the loss of ANG II and GFR becomes more dependent on blood pressure.
The RAS is upregulated in the kidney in response to a low sodium diet and in pathological states such as hemorrhagic shock and heart failure, and it stimulates sodium reabsorption in the proximal tubule by both direct and indirect effects. The AT 1A receptor is believed to be the primary receptor responsible for the vascular and tubular actions of the RAS in the kidney. Loss of either AGT or the AT 1A receptor results in chronic loss of extracellular volume and lowering of blood pressure (1). Volume expansion is able to increase blood pressure in AT 1A receptor-deficient mice to levels observed in control mice. Both AGT and AT 1A /AT 1B deficient mice exhibit a deficiency in the ability to concentrate urine, which is markedly exaggerated when sodium intake is reduced. Part of this effect may be related to the severe atrophy of the renal papilla observed in these mice.
The relationship between the RAS, renal perfusion pressure, and sodium excretion (pressure natriuresis) has been extensively examined in both rats and dogs. The RAS is believed to be a key player in this relationship via its actions on proximal tubular sodium reabsorption and renal vascular tone. Although pressure natriuresis studies have not yet been performed in AGT-, AT 1A -, or AT 1A /AT 1B -deficient mice, one would expect this relationship to be shifted to the left to normalize sodium and water excretion given the lower arterial pressures observed in these mice. Pressure natriuresis studies have been performed in AT 2 receptor knockout mice (5) . The results of this study indicate that the relationship is shifted to the right such that AT 2 receptor knockout mice require higher renal perfusion pressures to excrete similar amounts of sodium to wild-type mice. This result is in contrast with pharmacological studies performed in rats, which demonstrated a leftward shift in response to inhibition of AT 2 receptors. AT 2 receptor knockout mice also failed to exhibit increases in medullary blood flow in response to the increase in renal perfusion pressure. However, it is unclear whether these effects are directly related to lack of AT 2 receptors in the renal vasculature or compensation by another regulatory system.
Renal development
One of the most interesting areas to arise from gene targeting the RAS has been the role of the RAS in renal development. ANG II has a widely recognized growth and proliferative effect in VSMC, mesangial cells, and renal tubular cells that is mediated via AT 1 receptors. Mice in which the AGT or ACE gene has been disrupted are born in expected numbers, but most mice die before 3 wk of age. Death in these mice is associated with a variety of vascular and tubular pathologies that are surprisingly restricted to the kidney. These include thickening of arterial walls, cortical inflammation, and hypoplasia of the inner medulla. Interestingly, the degree of the renal pathology and frequency of lethality differs between the two AGT knockout strains previously described, perhaps due to difference in genetic background between the strains. Systemic expression of both human renin and human AGT is able to rescue the renal and lethal phenotypes when bred onto the AGT knockout background (3). However, when the expression of the human AGT gene is restricted to the proximal tubule, expression of the human transgenes is not able to rescue the lethal phenotype (Ding and Sigmund, unpublished observations). This suggests that loss of tubular ANG II is not the cause of lethality and that a vascular-derived source of ANG II in the kidney may be essential to prevent the lethality observed in AGT knockout mice. Whether this renal vascular source of ANG II can be derived from the plasma alone or requires synthesis directly by renal blood vessels has yet to be determined.
The vascular and tubular pathologies found in AGT and ACE knockout mice are not exhibited to the same extent in "The RAS is believed to be a key player in this relationship via its actions on proximal tubular sodium reabsorption.…" mice lacking only the AT 1A receptor but are recapitulated in mice that lack both the AT 1A and AT 1B receptors (10) . This is an interesting finding given that the vast majority of AT 1 receptors in the adult kidney are of the AT 1A subtype. It is possible that the expression of AT 1B receptors in early development is able to compensate for and limit the abnormalities in renal development; however, the expression pattern of the AT 1B receptor in the kidney of AT 1A knockout mice has yet to be reported.
Future directions
Clearly, the greatest limitation in the study of RAS knockout mice is the lethal phenotype that is exhibited shortly after birth. Although these mice have revealed a role for the RAS in the developing kidney, cardiovascular phenotyping of these mice has been more difficult. Also, since components of the RAS are expressed in a wide variety of tissue and cell types that all have important roles in cardiovascular regulation, it is difficult to specifically address the contribution of various tissue RAS in mice that have a global loss of gene function. Recently, it has become feasible to perform tissue-specific deletion of a gene via the use of specific recombinases. The Cre-loxP system from bacteriophage P1 has become a popular means of performing tissue-specific deletions of genes in vivo ( Fig. 2A) . We have incorporated this system to dissect the role of the various tissue RAS in a model of ANG II-dependent hypertension (13) . By placing loxP sites around the ANG II coding regions of the human AGT gene, we have been able to perform tissue-specific deletion of this gene in the liver via adenoviral delivery of the cre recombinase (Fig. 2, B and C) . The generation of transgenic mice harboring the cre recombinase in specific tissues and cell types will allow for a more detailed dissection of the RAS in the future (Table 1) . Finally, using temporally controlled promoters, one will be able to inactivate genes of the RAS at any time during development. Hopefully, this will bypass the lethal phenotypes and allow for a more thorough examination of the role of the various tissue RAS in cardiovascular regulation. Moreover, the use of targeted homologous recombination in which genes can be placed in the mouse genome at identical sites in a single copy will allow for the determination of the functional significance (Fig. 1) . Granulocytes are important representatives of the innate immune system. They evade the blood stream to phagocytose invading microbes or dead tissue. They are not capable of recirculating and die within days of performing their task. Monocytes migrate into tissues, in which they settle and become resident macrophages. Macrophages process internalized microbes and present major histocompatability complex (MHC) class II-bound antigen to lymphocytes. Under certain circumstances, macrophages differentiate into dendritic cells, the body's most efficient and versatile antigen-presenting cells. Lymphocytes represent the antigen-specific immune system. Lymphocytes survey the body for the presence of antigens. Naive lymphocytes home in to secondary lymphoid organs to meet antigen-presenting cells and to become antigenspecific effector lymphocytes. Plasma cells and effector T lymphocytes leave the lymph node to reach the blood stream, from where they are recruited into peripheral tissue. Cytotoxic T lymphocytes (CTL) eliminate antigen-bearing cells through the perforin/ granzyme, fas/fas ligand, or cytokine pathway. In peripheral tissues, helper T lymphocytes amplify macrophage function by release of activating cytokines. Anti-
